MelanomaPhase 1NCT01753089
Dendritic Cell Activating Scaffold in Melanoma
A Phase 1 study testing WDVAX in people with Melanoma, run by Dana-Farber Cancer Institute at 2 sites in United States.
Trial summary
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of investigational melanoma vaccines. Phase I studies also try to define the appropriate dose of the investigational vaccine, in this case WDVAX, to use for further studies. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Melanoma
- What is being tested?
- WDVAX
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 23 participants
- Where
- 2 sitesUnited States
- Study dates
- Jun 2013to 4 Aug 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically or cytologically confirmed Stage IV melanoma
- Life expectancy of 6 months or greater
- At least four weeks since treatment
- Recovered from any acute toxicity associated with prior therapy
- At least 8 weeks since treatment with any check point blockade agent
Who cannot join
- Known allergy or adverse reaction to PLG
- Pregnant or breastfeeding
- Receiving other investigational study agents
- Active autoimmune disease requiring treatment for suppression of inflammation
- Uncontrolled intercurrent illness
- History of a different malignancy unless disease-free for at least 5 years or diagnosed and treated cervical cancer in situ, basal or squamous cell carcinoma of the skin
- HIV positive
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Brigham and Women's Hospital
Boston, Massachusetts, 02215
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
About this study
Official title: A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of investigational melanoma vaccines. Phase I studies also try to define the appropriate dose of the investigational vaccine, in this case WDVAX, to use for further studies. "Investigational" means that the vaccine is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not yet approved WDVAX for any use in patients, including people with Melanoma.
The purpose of this study is to determine if it is possible to make a vaccine against melanoma by using your own melanoma tumor cells and combining them with other proteins which activate the immune system. We hope that by combining the cells and the proteins in this way that the vaccine will cause your own immune system to react against your melanoma tumor cells. The purpose of this study is also to determine the safest way to give this vaccine with the least amount of side effects.
Each vaccine will contain your own tumor cells which have been killed by a freezing and thawing process which destroys the cells but keeps the proteins from the melanoma cells. This is called a "tumor lysate" Your tumor lysate is combined with other proteins which activate the immune system. The other proteins are called GM-CSF and CpG. All of this is held together to form a "tablet" or "scaffold" which is about the size of a regular aspirin tablet. The material that holds the protein together is called PLGA. PLGA is the same material that doctors use for "dissolvable stitches" If you have ever had a problem with these types of stitches in the past, be sure to let your study doctor know about this.
Read the detailed description
After agreeing to participate you will be asked to undergo some screening tests or procedures to confirm that you are eligible for the study. Many of these test and procedures are likely to be part of regular cancer care and may be done even if it turns out that you do not take part in the research study. If you have had some of these tests or procedures recently, they may or may not have to be repeated. These procedures include: a medical history, physical examination, performance status, assessment of your tumor and blood tests.
If these tests show that you are eligible to participate in the research study, you will be referred to a study surgeon to prepare for the surgical removal of tumor tissue from which your vaccine will be made. If, at the time of your surgery, the surgeons are not able to obtain enough tumor cells for us to make your vaccine, then you will not be eligible to participate in this research study. The surgery will be performed at Brigham and Women's Hospital.
The total number of vaccines to be administered to each participant is four. Since we are looking for the shortest amount of time between doses that can be administered safely without severe or unmanageable side effects in participants that have melanoma, not everyone who participates in this research study will be on the same dose schedule to receive the vaccine. For example, some participants will receive the vaccine once a month for 4 doses, the next group will receive the vaccine every three weeks for 4 doses and the final group will receive the vaccine every two weeks for four doses. The schedule for your vaccination will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses.
Before each vaccination and then 24 hours after each vaccination you will have a physical exam and you will be asked questions about your general health and specific questions about any problems that you might be having and any medications you may be taking.
We will assess your tumor by CT scan and/or MRI before you start the vaccine, approximately half-way through the vaccine schedule and then one month after completion of all four vaccines. After that we will assess your tumor every three months.
We will monitor you for any side effects from the vaccine throughout all of the vaccine administration and for one month following completion of vaccinations or until all side effects are gone. We will assess your tumor again half-way through the vaccine administrations, one month and three months after completing all four vaccinations and then every three months after that. We will also continue to follow you to collect information regarding any other therapies you receive after vaccination is complete to keep track of any responses that you might have to other therapies in the future.
Further, we would like to keep track of your medical condition for the rest of your life. We would like to do this by calling you on the telephone once a year to see how you are doing. Keeping in touch with you and checking your condition every year helps us look at the long term effects of the research study.
Because different groups of participants will receive their vaccinations at different times (depending on when you are enrolled), we will provide you with your own calendar that is specific to the scheduling of your vaccine administration and all of your clinic visits and tests. The over-all schedule for the research study plan is described below.
If after completion of screening you are still eligible and the tumor collection for your surgery has been successful then there will be about a three week time period for you to recover from the surgery and for us to make your vaccine in our laboratory at DFCI.
As described above you will receive a total of four vaccinations. On the day you receive a vaccination, you will first undergo blood tests, a brief physical exam and update of your medical record. If you are still eligible ot proceed, one of the study surgeons will implant the vaccine by first washing a small area on your arm, leg or torso with sterilizing soap. Then they will make a small incision in your skin and create a small "pocket" between teh upper layer of skin and the tissue underneath. Using sterile surgical tools they will slide the vaccine "tablet" into this pocket and then use 2-3 stitches to close the incision. This site will be covered with a sterile bandage and the surgeon will ask you to return the following day so that he or she or one of the other study team members may check the vaccine site.
Depending on when you are enrolled in the study, you will receive your vaccines either; every 4 weeks, every 3 weeks or every 2 weeks for a total of 4 vaccines. We will be able to tell you the schedule at the time that you are enrolled on the study. We will be able to give you a copy of your study calendar after our laboratory has processed your tumor sample.
If there are enough tumor cells left over from your vaccine preparation, we will irradiate them to kill them and give them to you as an injection under the skin at the time of your first vaccination and your last vaccination. This injection will be given at a site different from where the vaccinations are placed. This is called a "DTH test" and is one way to help us monitor activity of your immune system.
If you receive this DTH test, we will perform a small skin biopsy called a "punch biopsy" of the DTH injection site about 3-5 days following the second DTH injection (3-5 days following the last vaccination).
If we can see a vaccine injection site reaction (redness, swelling, etc.) at the vaccination site then we will also perform a punch biopsy of the vaccination site about 3-5 days following vaccination Number 2 and Number 4.
If at any time during the course of the vaccinations or after you complete all four vaccinations you have easily accessible tumor that shows signs of an inflammatory reaction to the vaccine we may also biopsy the tumor. The purpose of this is for us to learn what sort of cells from the immune system may become activated against the tumor when you ar receiving vaccine or following vaccination.
- Conditions
- Melanoma
- Being tested
- WDVAX
- Keywords
- Metastatic
- Medical subject headings
- Melanoma, Neoplasm Metastasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WDVAXBiological
| Study group | Role | What they receive |
|---|---|---|
| WDVAX | Other | Treatment Receives: Biological: WDVAX |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of WDVAX for Metastatic Melanoma
To determine the feasibility of preparing dendritic cells activating scaffolds (WDVAX) incorporating autologous melanoma cell lysates in patients with metastatic melanoma
Measured: 2 years
Safety and Biologic Activity of WDVAX
To determine the safety and biologic activity of vaccination with dendritic cell activation scaffolds (WDVAX) incorporating autologous melanoma cell lysates in patients with metastatic melanoma
Measured: 2 years
Secondary outcomes (4)
Immune Response
Measured: 2 years
Tumor Response
Measured: 2 years
Survival
Measured: 2 years
Response to subsequent immunotherapy (E.G., anit-CTLA-4 or anti_PD-1mAbs
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Dec 2012 (estimated)
- Study startJun 2013
- Primary completion4 Aug 2025
- Study completion4 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MelanomaStudies of the same condition, open and under way.
- More trials run by Dana-Farber Cancer InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 23 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dana-Farber Cancer Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, F. Stephen Hodi, MD, Dana-Farber Cancer Institute
- Investigators
- F. Stephen Hodi, MD, Principal investigator, Dana-Farber Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01753089
- Sponsor's protocol ID
- 12-306
- Status last verified
- Sep 2025
- First submitted
- 17 Dec 2012
- Last updated
- 15 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients
- ClinicalTrials.gov ID
- NCT01753089
- Acronym / sponsor ID
- 12-306
- Conditions
- Melanoma
- Keywords
- Metastatic
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 23 participants (actual)
- Lead sponsor
- Dana-Farber Cancer InstituteUniversity, hospital or other
- Study start
- Jun 2013 (actual)
- Primary completion
- 4 Aug 2025 (actual)
- Study completion
- 4 Aug 2025 (actual)
- First posted
- 20 Dec 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of investigational melanoma vaccines. Phase I studies also try to define the appropriate dose of the investigational vaccine, in this case WDVAX, to use for further studies. "Investigational" means that the vaccine is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not yet approved WDVAX for any use in patients, including people with Melanoma.
The purpose of this study is to determine if it is possible to make a vaccine against melanoma by using your own melanoma tumor cells and combining them with other proteins which activate the immune system. We hope that by combining the cells and the proteins in this way that the vaccine will cause your own immune system to react against your melanoma tumor cells. The purpose of this study is also to determine the safest way to give this vaccine with the least amount of side effects.
Each vaccine will contain your own tumor cells which have been killed by a freezing and thawing process which destroys the cells but keeps the proteins from the melanoma cells. This is called a "tumor lysate" Your tumor lysate is combined with other proteins which activate the immune system. The other proteins are called GM-CSF and CpG. All of this is held together to form a "tablet" or "scaffold" which is about the size of a regular aspirin tablet. The material that holds the protein together is called PLGA. PLGA is the same material that doctors use for "dissolvable stitches" If you have ever had a problem with these types of stitches in the past, be sure to let your study doctor know about this.
Detailed description
After agreeing to participate you will be asked to undergo some screening tests or procedures to confirm that you are eligible for the study. Many of these test and procedures are likely to be part of regular cancer care and may be done even if it turns out that you do not take part in the research study. If you have had some of these tests or procedures recently, they may or may not have to be repeated. These procedures include: a medical history, physical examination, performance status, assessment of your tumor and blood tests.
If these tests show that you are eligible to participate in the research study, you will be referred to a study surgeon to prepare for the surgical removal of tumor tissue from which your vaccine will be made. If, at the time of your surgery, the surgeons are not able to obtain enough tumor cells for us to make your vaccine, then you will not be eligible to participate in this research study. The surgery will be performed at Brigham and Women's Hospital.
The total number of vaccines to be administered to each participant is four. Since we are looking for the shortest amount of time between doses that can be administered safely without severe or unmanageable side effects in participants that have melanoma, not everyone who participates in this research study will be on the same dose schedule to receive the vaccine. For example, some participants will receive the vaccine once a month for 4 doses, the next group will receive the vaccine every three weeks for 4 doses and the final group will receive the vaccine every two weeks for four doses. The schedule for your vaccination will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses.
Before each vaccination and then 24 hours after each vaccination you will have a physical exam and you will be asked questions about your general health and specific questions about any problems that you might be having and any medications you may be taking.
We will assess your tumor by CT scan and/or MRI before you start the vaccine, approximately half-way through the vaccine schedule and then one month after completion of all four vaccines. After that we will assess your tumor every three months.
We will monitor you for any side effects from the vaccine throughout all of the vaccine administration and for one month following completion of vaccinations or until all side effects are gone. We will assess your tumor again half-way through the vaccine administrations, one month and three months after completing all four vaccinations and then every three months after that. We will also continue to follow you to collect information regarding any other therapies you receive after vaccination is complete to keep track of any responses that you might have to other therapies in the future.
Further, we would like to keep track of your medical condition for the rest of your life. We would like to do this by calling you on the telephone once a year to see how you are doing. Keeping in touch with you and checking your condition every year helps us look at the long term effects of the research study.
Because different groups of participants will receive their vaccinations at different times (depending on when you are enrolled), we will provide you with your own calendar that is specific to the scheduling of your vaccine administration and all of your clinic visits and tests. The over-all schedule for the research study plan is described below.
If after completion of screening you are still eligible and the tumor collection for your surgery has been successful then there will be about a three week time period for you to recover from the surgery and for us to make your vaccine in our laboratory at DFCI.
As described above you will receive a total of four vaccinations. On the day you receive a vaccination, you will first undergo blood tests, a brief physical exam and update of your medical record. If you are still eligible ot proceed, one of the study surgeons will implant the vaccine by first washing a small area on your arm, leg or torso with sterilizing soap. Then they will make a small incision in your skin and create a small "pocket" between teh upper layer of skin and the tissue underneath. Using sterile surgical tools they will slide the vaccine "tablet" into this pocket and then use 2-3 stitches to close the incision. This site will be covered with a sterile bandage and the surgeon will ask you to return the following day so that he or she or one of the other study team members may check the vaccine site.
Depending on when you are enrolled in the study, you will receive your vaccines either; every 4 weeks, every 3 weeks or every 2 weeks for a total of 4 vaccines. We will be able to tell you the schedule at the time that you are enrolled on the study. We will be able to give you a copy of your study calendar after our laboratory has processed your tumor sample.
If there are enough tumor cells left over from your vaccine preparation, we will irradiate them to kill them and give them to you as an injection under the skin at the time of your first vaccination and your last vaccination. This injection will be given at a site different from where the vaccinations are placed. This is called a "DTH test" and is one way to help us monitor activity of your immune system.
If you receive this DTH test, we will perform a small skin biopsy called a "punch biopsy" of the DTH injection site about 3-5 days following the second DTH injection (3-5 days following the last vaccination).
If we can see a vaccine injection site reaction (redness, swelling, etc.) at the vaccination site then we will also perform a punch biopsy of the vaccination site about 3-5 days following vaccination Number 2 and Number 4.
If at any time during the course of the vaccinations or after you complete all four vaccinations you have easily accessible tumor that shows signs of an inflammatory reaction to the vaccine we may also biopsy the tumor. The purpose of this is for us to learn what sort of cells from the immune system may become activated against the tumor when you ar receiving vaccine or following vaccination.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| WDVAX | Other | Biological: WDVAXTreatment |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Histologically or cytologically confirmed Stage IV melanoma
- Life expectancy of 6 months or greater
- At least four weeks since treatment
- Recovered from any acute toxicity associated with prior therapy
- At least 8 weeks since treatment with any check point blockade agent
Key exclusion criteria (7 listed)
- Known allergy or adverse reaction to PLG
- Pregnant or breastfeeding
- Receiving other investigational study agents
- Active autoimmune disease requiring treatment for suppression of inflammation
- Uncontrolled intercurrent illness
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| WDVAX | Biological | WDVAX |
Primary outcome
Feasibility of WDVAX for Metastatic Melanoma
Time frame: 2 years
To determine the feasibility of preparing dendritic cells activating scaffolds (WDVAX) incorporating autologous melanoma cell lysates in patients with metastatic melanoma
Safety and Biologic Activity of WDVAX
Time frame: 2 years
To determine the safety and biologic activity of vaccination with dendritic cell activation scaffolds (WDVAX) incorporating autologous melanoma cell lysates in patients with metastatic melanoma
4 secondary outcomes
Immune Response
Time frame: 2 years
Tumor Response
Time frame: 2 years
Survival
Time frame: 2 years
Response to subsequent immunotherapy (E.G., anit-CTLA-4 or anti_PD-1mAbs
Time frame: 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2025.
Related trials for Melanoma
Not yet recruitingPhase 1
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
Hepatocellular Carcinoma, Renal Cell Carcinoma
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Not yet recruiting
Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D System.
Naevi
Not yet recruitingPhase 1
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors
RecruitingObservational study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
F. Stephen Hodi, MD principal investigator
Dana-Farber Cancer Institute
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing WDVAX in people with Melanoma, run by Dana-Farber Cancer Institute at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of WDVAX for Metastatic Melanoma (time frame: 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2025.